Inappropriate prescribing of proton pump inhibitors in older patients: Effects of an educational strategy

Drugs and Aging

Volumn 29, Issue 8, 2012, Pages 681-690

  Hamzat, Hanifat ^a   Sun, Hao ^a   Ford, Joanna C ^b   MacLeod, Joan ^c   Soiza, Roy L ^a,b   Mangoni, Arduino A ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b WOODEND HOSPITAL   (United Kingdom)

^c NHS GRAMPIAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE;

AGED; ARTICLE; DEMENTIA; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT EDUCATION; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; FEMALE; FRAIL ELDERLY; HOSPITALS; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; PATIENT EDUCATION AS TOPIC; PRIMARY HEALTH CARE; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 84864143807     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11632700     Document Type: Article

References (37)

1. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64 (10): 935-51
2. Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf 2010; 19 (10): 1019-24
3. Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1. Int J Clin Pharmacol Ther 2003; 41 (5): 207-12
4. Martin RM, Lim AG, Kerry SM, et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998; 12 (8): 797-805
5. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317 (7156): 452-6
6. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008; 336 (7634): 2-3
7. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011; 56 (4): 931-50
8. McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010; 26 (6): 624-31
9. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009; 122 (10): 896-903
10. Jackson SH, Mangoni AA, BattyGM. Optimization of drug prescribing. Br J Clin Pharmacol 2004; 57 (3): 231-6
11. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57 (1): 6-14
12. Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137 (1): 80-7, 87
13. Niklasson A, Lindstrom L, Simren M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010; 105 (7): 1531-7
14. Jones MI, Greenfield SM, Jowett S, et al. Proton pump inhibitors: a study of GPs prescribing. Fam Pract 2001; 18 (3): 333-8
15. de GV, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56 (3): 221-9
16. Hall WH, Ramachandran R, Narayan S, et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004; 4: 94
17. Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol 2008; 14 (8): 1149-55
18. Proton pump inhibitors. In: British Medical Association and the Royal Pharmaceutical Society. British national formulary. 61st ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2011
19. National Institute of Clinical Excellence (NICE). Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. NICE Technology Appraisal Guidance No. 7. London: NICE, 2000
20. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011; 22 (2): 205-10
21. Shrestha K, Hughes JD, Lee YP, et al. The prevalence of coadministration of clopidogrel and proton pump inhibitors. Qual Prim Care 2011; 19 (1): 35-42
22. van Dijk KN, ter Huurne K, de Vries CS, et al. Prescribing of gastroprotective drugs among elderly NSAID users in the Netherlands. Pharm World Sci 2002; 24 (3): 100-3
23. Ntaios G, Chatzinikolaou A, Kaiafa G, et al. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med 2009; 20 (2): 171-3
24. Gillen D, McColl KE.Does concern aboutmissing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999; 94 (1): 75-9
25. Wayman J, Hayes N, Raimes SA, et al. Prescription of proton pump inhibitors before endoscopy: a potential cause of missed diagnosis of early gastric cancers. Arch Fam Med 2000; 9 (4): 385-8
26. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25 (5): 333-40
27. Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000; 46 (4): 464-7
28. Brauner DJ, Muir JC, Sachs GA. Treating nondementia illnesses in patients with dementia. JAMA 2000; 283 (24): 3230-5
29. Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patientdirected strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther 2004; 19 (8): 917-22
30. Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83 (975): 66-8
31. van Vliet EP, Steyerberg EW, Otten HJ, et al. The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards. Aliment Pharmacol Ther 2009; 29 (2): 213-21
32. Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39 (5): 649-53
33. Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13 (2): 145-53
34. Farup PG, Juul-Hansen PH, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol 2001; 33 (3): 206-9
35. Howden CW, Kahrilas PJ. Editorial: just how "difficult" is it to withdraw PPI treatment? Am J Gastroenterol 2010; 105 (7): 1538-40
36. IshiharaM, Ito M. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. Eur J Pharmacol 2002; 444 (3): 209-15
37. Khalil T, Singh P, Fujimura M, et al. Effect of aging on gastric acid secretion, serum gastrin, and antral gastrin content in rats. Dig Dis Sci 1988; 33 (12): 1544-8